IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

Published on December 30, 2024

Tumors (NETs), respectively 85% and 20-40% Rational combination opportunities with IDEAYA’s DNA Damage Repair (DDR) clinical pipeline,

Continue reading on website
Other news

Experience Hakka Heritage: Hakka Yu Opens Its First International Outlet at Jewel Changi Airport

December 30, 2024
venture outside China, this milestone marks a celebration of cultural heritage and culinary artistry, offering Singaporeans and global

Hoe verhalen onze werkelijkheid buigzaam maken

December 30, 2024
Bezoek je een communicatiebureau, dan hoor je al snel het buzzword ‘storytelling’. De verhalen waren er altijd al, maar tegenwoordig is